Advances in Type 1 diabetes therapeutics: immunomodulation and beta-cell salvage.
Endocrinol Metab Clin North Am
; 38(2): 303-17, viii, 2009 Jun.
Article
in En
| MEDLINE
| ID: mdl-19328413
ABSTRACT
Refinements in our understanding of the pathogenic mechanisms of Type 1 diabetes from studies of animal models and clinical observation have led to new clinical trials to prevent disease progression and restore the loss of beta-cells that defines the disease. Antigen-specific agents have shown initial promise and non-antigen-specific agents now have improved safety compared with older agents. In addition, preclinical studies with other agents have shown efficacy. Ultimately, a combination of immunologic and cellular therapies may be needed to restore metabolic control. Agents that augment recovery of dysfunctional beta-cells, and other compounds that may be able to induce beta-cell replication, are logical additions once immune tolerance is achieved.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Diabetes Mellitus, Type 1
/
Insulin-Secreting Cells
/
Immunotherapy
Limits:
Animals
/
Humans
Language:
En
Journal:
Endocrinol Metab Clin North Am
Journal subject:
ENDOCRINOLOGIA
/
METABOLISMO
Year:
2009
Document type:
Article
Affiliation country:
United States